Italfarmaco Drug Patent Portfolio
Italfarmaco owns 2 orange book drugs protected by 5 US patents Given below is the list of Italfarmaco's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10688047 | Physically and chemically stable oral suspensions of givinostat | 28 Oct, 2036 | Active |
| US9421184 | Diethyl-[6-(4-hydroxycarbamoyl-phenyl-carbamoyloxy-methyl)-naphthalen-2-yl-methyl]-ammonium chloride for use in the treatment of muscular dystrophy | 03 Feb, 2032 | Active |
| US9867799 | Diethyl-[6-(4-hydroxycarbamoyl-phenyl-carbamoyloxy-methyl)-naphthalen-2-yl-methyl]-ammonium chloride for use in the treatment of muscular dystrophy | 03 Feb, 2032 | Active |
| US8765150 | Riluzole aqueous suspensions | 12 Mar, 2029 | Active |
| US7329689 | Monohydrate hydrochloride of the 4-hydroxycarbamoyl-phenyl)-carbamic acid (6-diethylaminomethyl-naphtalen-2-yl) ester | 15 Jan, 2026 | Active |
Latest Legal Activities on Italfarmaco's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Italfarmaco.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Patent Term Extension Application under 35 USC 156 Filed | 17 May, 2024 | US9867799 |
| Patent Term Extension Application under 35 USC 156 Filed | 17 May, 2024 | US10688047 |
| Patent Term Extension Application under 35 USC 156 Filed | 17 May, 2024 | US9421184 |
| Patent Term Extension Application under 35 USC 156 Filed | 17 May, 2024 | US7329689 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 15 May, 2024 | US9867799 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 15 May, 2024 | US9421184 |
|
Email Notification
Critical
| 15 May, 2024 | US9867799 |
|
Email Notification
Critical
| 15 May, 2024 | US9421184 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 23 Feb, 2024 | US9421184 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 26 Dec, 2023 | US10688047 |
|
Interim Patent Term Extension Granted
Critical
| 21 Nov, 2023 | US7329689 |
|
Email Notification
Critical
| 03 Aug, 2023 | US7329689 |
|
Electronic Review
Critical
| 02 Aug, 2023 | US7329689 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 31 Jul, 2023 | US7329689 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 03 Jan, 2022 | US8765150 |
Italfarmaco's Family Patents
Italfarmaco Drug List
Given below is the complete list of Italfarmaco's drugs and the patents protecting them.
1. Duvyzat
Duvyzat is protected by 4 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10688047 | Physically and chemically stable oral suspensions of givinostat |
28 Oct, 2036
(10 years from now)
| Active |
| US9421184 | Diethyl-[6-(4-hydroxycarbamoyl-phenyl-carbamoyloxy-methyl)-naphthalen-2-yl-methyl]-ammonium chloride for use in the treatment of muscular dystrophy |
03 Feb, 2032
(6 years from now)
| Active |
| US9867799 | Diethyl-[6-(4-hydroxycarbamoyl-phenyl-carbamoyloxy-methyl)-naphthalen-2-yl-methyl]-ammonium chloride for use in the treatment of muscular dystrophy |
03 Feb, 2032
(6 years from now)
| Active |
| US7329689 | Monohydrate hydrochloride of the 4-hydroxycarbamoyl-phenyl)-carbamic acid (6-diethylaminomethyl-naphtalen-2-yl) ester |
15 Jan, 2026
(6 days from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Duvyzat's drug page
2. Tiglutik Kit
Tiglutik Kit is protected by 1 patent, which is still active. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8765150 | Riluzole aqueous suspensions |
12 Mar, 2029
(3 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Tiglutik Kit's drug page